A Multicenter Retrospective Study on the Safety and Efficacy of the Surpass Evolve Flow Diverter System for the Treatment of Intracranial Aneurysms

Objective: To evaluate the safety and efficacy of the Surpass Evolve flow diverter system for the treatment of intracranial aneurysms across three medical centers. Methods: A retrospective review was conducted on patients with intracranial aneurysms treated with the Surpass Evolve FDS between March 2023 and May 2024 at three participating centers. Primary outcome measures included the rate of complete aneurysm occlusion (Raymond-Roy class 1) and the incidence of periprocedural major stroke and mortality. Secondary outcomes encompassed follow-up modified Rankin Scale (mRS) scores, imaging assessment results, and complication rates. Results: A total of 132 patients (132 aneurysms) were included. The median age was 60.0 years (IQR 52.5?69.0), and 80 patients (66.6%) were female. The complete occlusion rate was 73.3% (88/120). The rate of major stroke was 2.3%, with no procedure-related mortality. At follow-up, 96.9% of patients had an mRS score of 0?2. Multivariate analysis identified non-use of an intraprocedural IIb/IIIa inhibitor and the absence of a branch arising from the aneurysm as independent predictors of complete occlusion. Conclusion: In this real-world, multicenter, retrospective study, the treatment of intracranial aneurysms with the Surpass Evolve FDS was associated with a high rate of complete occlusion and a favorable safety profile. Our findings indicate that complete occlusion was independently predicted by two key factors: periprocedural avoidance of IIb/IIIa inhibitors and a favorable aneurysm morphology without incorporated branches.